Latest news
Loading news…
ADEL is developing therapeutic and diagnostic agents for neurological diseases, particularly Alzheimer's disease.
ADEL on Acquirezy — acquisitions, funding rounds, investments, investors, key people & contacts.
Total Funding
$14.8M
Funding Rounds
4
Last Funding
Acquisitions
0
Monthly Visits
Contacts
6
About ADEL
Funding & Financials
- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
Web Traffic
- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Company Info
- Org types
- company
- HQ
- Seoul, Seoul-t'ukpyolsi, South Korea
ADEL Funding Rounds
4 results
Upgrade to Pro to view this datasetUpgrade
| Organization Name | Funding Type | Lead Investor Names | Org Hq Country | ||
|---|---|---|---|---|---|
1–4 of 4Show
Page 1 / 1
6
professional contacts at ADEL
Contact execs at ADEL →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Bulk Dataset Export
Need the data in bulk? Buy the entire dataset.
5.4M company profiles200K+ acquisitions700K+ funding rounds327K investors2M+ people61M contacts45K schools
Delivered as CSV, JSON or Parquet — at startup-friendly pricing.
FAQs about ADEL
People who checked this page also checked these
Browse the full Acquirezy directory.